Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk (HBR) Patients With History of Paroxysmal Atrial Fibrillation

Next Previous
X
Search
Trial Profile

Safety and Efficacy of Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk (HBR) Patients With History of Paroxysmal Atrial Fibrillation

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Coronary artery disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms INTERMITTENT

    • Most Recent Events

    • 12 Aug 2022 Trial design changed to observational, case-control
    • 12 Aug 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2023.
    • 12 Aug 2022 Planned primary completion date changed from 30 Nov 2020 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top